Outlook Therapeutics Reports Q3 Revenue
Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company focused on ophthalmic treatments, released its third quarter fiscal 2025 results on August 14, 2025. The company posted its first-ever commercial revenue from European sales of LYTENAVA (bevacizumab gamma), reaching $1.5 million (GAAP) and matching analyst expectations. Non-GAAP adjusted loss per share improved to $0.44, while the company’s adjusted net loss narrowed to $15.8 million. However, cash reserves (GAAP) were $8.9 million. The quarter represented a clear shift as Outlook Therapeutics moves from the clinical stage to commercial operations, but ongoing U.S. regulatory approval and capital needs remain in focus.
Source: Analyst estimates for the quarter provided by FactSet.
Outlook Therapeutics develops treatments for eye diseases, specializing in medicines delivered by intravitreal injection—directly into the eye—for retinal conditions. Its lead commercial product, LYTENAVA (bevacizumab gamma), is an ophthalmic formulation of the cancer drug bevacizumab, repurposed in an authorized version for eye use. The product launched in Germany and the United Kingdom in the latest quarter, signaling the company’s first step into sales and revenue generation after years in clinical development.
Source Fool.com
